Medtech Startup Biomarx Secures £700K Pre-Seed Funding to Advance…

Team S · 2026-01-07T13:04:46.000Z

Biomarx, an early-stage MedTech and biotech startup focused on transforming cancer diagnostics through automated liquid biopsy technology, has successfully raised £700,000 in pre-seed funding to accelerate development of its innovative genomic diagnostic platform. Based in the UK, the company is building an automated plug-and-play system designed to lower cost and complexity barriers in genomic cancer testing a move that could help democratise access to personalised cancer care and clinical decision-making globally. The £700K pre-seed funding round was led by SFC Capital and Clarendon Fund Managers, with additional backing from the University of Strathclyde, InterTradeIreland’s Seedcorn Competition, TechStart Ventures (proof-of-concept grant) and angel investors- collectively supporting Biomarx’s progression from proof of concept to a minimum viable product capable of clinical validation. This capital injection will also support ISO 13485 accreditation efforts and a lab-based preliminary clinical study focusing on Non-Small Cell Lung Cancer (NSCLC) enabling earlier detection and more precise treatment stratification using circulating tumour DNA (ctDNA). Biomarx’s platform is engineered to reduce the technical and cost hurdles traditionally tied to next-generation sequencing diagnostics, paving the way for wider clinical adoption of liquid biopsy testing and closing gaps in personalised care accessibility. Founder Sean Macfarlane emphasised that the funding allows the team to move decisively into product development and early clinical validation, with an immediate focus on building a robust, automated and accessible solution that can rapidly deliver high-quality results. The company will be based in Glasgow, where it will collaborate closely with the University of Strathclyde - an institution recognised for its strong track record in deep-tech commercialisation and diagnostic innovation — to further mature its technology and bring it closer to market readiness. #Biomarx #MedTech #LiquidBiopsy #CancerDiagnostics #PreSeedFunding #GenomicTesting #HealthTech #StartupFunding #PersonalisedMedicine #Innovation #HealthcareAI #MedicalInnovation

Member Login Get Access

Medtech Startup Biomarx Secures £700K Pre-Seed Funding to Advance… | Newnex